Mechanisms Leading to Gut Dysbiosis in COVID-19: Current Evidence and Uncertainties Based on Adverse Outcome Pathways
- PMID: 36143044
- PMCID: PMC9505288
- DOI: 10.3390/jcm11185400
Mechanisms Leading to Gut Dysbiosis in COVID-19: Current Evidence and Uncertainties Based on Adverse Outcome Pathways
Abstract
Alteration in gut microbiota has been associated with COVID-19. However, the underlying mechanisms remain poorly understood. Here, we outlined three potential interconnected mechanistic pathways leading to gut dysbiosis as an adverse outcome following SARS-CoV-2 presence in the gastrointestinal tract. Evidence from the literature and current uncertainties are reported for each step of the different pathways. One pathway investigates evidence that intestinal infection by SARS-CoV-2 inducing intestinal inflammation alters the gut microbiota. Another pathway links the binding of viral S protein to angiotensin-converting enzyme 2 (ACE2) to the dysregulation of this receptor, essential in intestinal homeostasis-notably for amino acid metabolism-leading to gut dysbiosis. Additionally, SARS-CoV-2 could induce gut dysbiosis by infecting intestinal bacteria. Assessing current evidence within the Adverse Outcome Pathway framework justifies confidence in the proposed mechanisms to support disease management and permits the identification of inconsistencies and knowledge gaps to orient further research.
Keywords: ACE2 dysregulation; COVID-19; SARS-CoV-2 infection; gastrointestinal disorders; gut dysbiosis; intestinal inflammation; microbiota.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Pathophysiological mechanisms underlying gastrointestinal symptoms in patients with COVID-19.World J Gastroenterol. 2021 May 21;27(19):2341-2352. doi: 10.3748/wjg.v27.i19.2341. World J Gastroenterol. 2021. PMID: 34040326 Free PMC article. Review.
-
ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis.Ageing Res Rev. 2020 Sep;62:101123. doi: 10.1016/j.arr.2020.101123. Epub 2020 Jul 16. Ageing Res Rev. 2020. PMID: 32683039 Free PMC article. Review.
-
Gut as an Alternative Entry Route for SARS-CoV-2: Current Evidence and Uncertainties of Productive Enteric Infection in COVID-19.J Clin Med. 2022 Sep 26;11(19):5691. doi: 10.3390/jcm11195691. J Clin Med. 2022. PMID: 36233559 Free PMC article. Review.
-
Roles of the gut microbiota in severe SARS-CoV-2 infection.Cytokine Growth Factor Rev. 2022 Feb;63:98-107. doi: 10.1016/j.cytogfr.2022.01.007. Epub 2022 Jan 31. Cytokine Growth Factor Rev. 2022. PMID: 35131164 Free PMC article. Review.
-
Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential.World J Gastroenterol. 2022 Dec 21;28(47):6689-6701. doi: 10.3748/wjg.v28.i47.6689. World J Gastroenterol. 2022. PMID: 36620345 Free PMC article. Review.
Cited by
-
Gut microbe-host interactions in post-COVID syndrome: a debilitating or restorative partnership?Gut Microbes. 2024 Jan-Dec;16(1):2402544. doi: 10.1080/19490976.2024.2402544. Epub 2024 Sep 17. Gut Microbes. 2024. PMID: 39287023 Free PMC article. Review.
-
Infection with SARS-CoV-2 Is Associated with Elevated Levels of IP-10, MCP-1, and IL-13 in Sepsis Patients.Diagnostics (Basel). 2023 Mar 11;13(6):1069. doi: 10.3390/diagnostics13061069. Diagnostics (Basel). 2023. PMID: 36980378 Free PMC article.
-
A Reflection of Metabolic Syndrome through the Window of COVID-19.Vaccines (Basel). 2022 Nov 19;10(11):1966. doi: 10.3390/vaccines10111966. Vaccines (Basel). 2022. PMID: 36423061 Free PMC article.
-
Signatures of disease outcome severity in the intestinal fungal and bacterial microbiome of COVID-19 patients.Front Cell Infect Microbiol. 2024 Mar 6;14:1352202. doi: 10.3389/fcimb.2024.1352202. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38510960 Free PMC article.
-
Streptococcus salivarius and Ligilactobacillus salivarius: Paragons of Probiotic Potential and Reservoirs of Novel Antimicrobials.Microorganisms. 2025 Feb 28;13(3):555. doi: 10.3390/microorganisms13030555. Microorganisms. 2025. PMID: 40142448 Free PMC article. Review.
References
-
- Chidambaram V., Tun N.L., Haque W.Z., Majella M.G., Sivakumar R.K., Kumar A., Hsu A.T.-W., Ishak I.A., Nur A.A., Ayeh S.K., et al. Factors associated with disease severity and mortality among patients with COVID-19: A systematic review and meta-analysis. PLoS ONE. 2020;15:e0241541. doi: 10.1371/journal.pone.0241541. - DOI - PMC - PubMed
-
- Mudatsir M., Fajar J.K., Wulandari L., Soegiarto G., Ilmawan M., Purnamasari Y., Mahdi B.A., Jayanto G.D., Suhendra S., Setianingsih Y.A., et al. Predictors of COVID-19 severity: A systematic review and meta-analysis. F1000Research. 2020;9:1107. doi: 10.12688/f1000research.26186.1. - DOI - PMC - PubMed
-
- Clerbaux L.-A., Albertini M.C., Amigó N., Beronius A., Bezemer G.F.G., Coecke S., Daskalopoulos E.P., del Giudice G., Greco D., Grenga L., et al. Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. J. Clin. Med. 2022;11:4464. doi: 10.3390/jcm11154464. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous